LobbyingAvalyn Pharma lobbying by quarter
Avalyn Pharma AVLN's latest lobbying report covers Q2 2026, at $60K. The four quarters Q4 2025–Q3 2026 total $160K. Its first report covers Q4 2025; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
Avalyn PharmaAVLN
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $160K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $40K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $60K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$80K · 3 reports
- Medical research and clinical labs$80K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| Dla Piper | $160K | 3 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Dla Piper | $60K |
| 04/16for Q1 | Dla Piper | $60K |
| 01/16for Q4 2025 | Dla Piper | $40K |
| 25/12/15for Q4 2025 | Dla Piper | Under $5,000 |